Safety of Simultaneous Pneumococcal and Influenza Vaccination in Elderly Patients in Brazil

Toniolo-Neto, João; Weckx, Lily Yin; Halker, Elisa; Lopes, Carlos Renato; Succi, Regina Célia de Menezes; Paiva, Terezinha Maria de; Ishida, María Akíko; Forleo‐Neto, Eduardo

doi:10.2165/00002512-199915001-00006

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPV safety, including that with simultaneous influenza vaccination, has been well documented among older persons (57,95,101,129,144). The primary side effects are local reactions at the injection site.…”

Section: Vaccine Safetymentioning

confidence: 99%

Pneumococcal Vaccination and Revaccination of Older Adults

2003

View full text Add to dashboard Cite

As individuals advance in age, the risk of infection, bacteremia, and mortality caused by Streptococcus pneumoniae rises. Retrospective data demonstrate that the licensed penumococcal polysaccharide vaccine (PPV) is effective in older persons in reducing serotype-specific invasive disease. PPV demonstrates good immunogenicity in older adults, generally comparable to that in younger subjects, although certain cohorts respond less well. The response to PPV is T cell independent, however, and does not elicit immunologic memory. The duration of the anti-capsular polysaccharide antibody response appears to wane as early as 3 years after vaccination. In older persons, revaccination induces an antibody response, although it may not be as strong as that from the initial vaccine. While revaccination of older adults has been recommended, clinical efficacy has not yet been proven. Measures of antibody function may be at least as important in determining protection as are quantitative antibody levels. Additional studies of immunogenicity, particularly regarding revaccination, will facilitate the design of an optimal pneumococcal vaccination policy. Research into conjugate- and protein-based pneumococcal vaccines, which elicit T-cell-dependent responses and induce immunologic memory, is needed in older persons. In the meantime, administering to PPV to recommended groups should be a public health priority

show abstract

Section: Vaccine Safetymentioning

confidence: 99%

Pneumococcal Vaccination and Revaccination of Older Adults

2003

View full text Add to dashboard Cite

show abstract

“…Independent of the age of the patient, chronic conditions such as cardiovascular disease, pulmonary disease, diabetes mellitus and asthma can considerably increase the probability of severe or complicated influenza, requiring hospitalization, and increase the death rate by approximately 40-fold. Combined pulmonary and cardiovascular disease can increase the risk of death by 800-fold In early April 1999 about 9 million doses of influenza vaccine were administered to elderly people in Brazil 30 . The vaccination campaign among people older than 65 living in Iporanga reached 72.4% of the target population, suggesting significant protection against A/Bayern/7/95, which is antigenically and genetically related to A/Beijing/262/95, a component of the 1999 vaccine.…”

Section: Discusssionmentioning

confidence: 99%

Outbreak of influenza type A (H1N1) in Iporanga, São Paulo State, Brazil

Paiva

Ishida

Hanashiro

et al. 2001

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

SUMMARYFrom June to July 1999 an outbreak of acute respiratory illness occurred in the town of Iporanga. Out of a total of 4,837 inhabitants, 324 cases were notified to the Regional Surveillance Service. Influenza virus was isolated from 57.1% of the collected samples and 100% seroconversion to influenza A (H1N1) was obtained in 20 paired sera tested. The isolates were related to the A/ Bayern/07/95 strain (H1N1). The percentages of cases notified during the outbreak were 28.4%, 29.0%, 20.7%, 6.2% and 15.7% in the age groups of 0-4, 5-9, 10-14, 15-19 and older than 20 years, respectively. The highest proportion of positives was observed among children younger than 14 years and no cases were notified in people older than 65 years, none of whom had been recently vaccinated against influenza. These findings suggest a significant vaccine protection against A/Bayern/7/95, the H1 component included in the 1997-98 influenza vaccine for elderly people. This viral strain is antigenically and genetically related to A/Beijing/ 262/95, the H1 component of the 1999 vaccine. Vaccines containing A/Beijing/262/95 (H1N1) stimulated post-immunization hemagglutination inhibition antibodies equivalent in frequency and titre to both A/Beijing/262/95-like and A/Bayern/7/95-like viruses. Thus, this investigation demonstrates the effectiveness of vaccination against influenza virus in the elderly.

show abstract

“…The 23-valent pneumococcal polysaccharide vaccine is about 50-80% effective in preventing invasive pneumococcal disease among older persons (4). In Brazil, this vaccine was introduced in a national campaign initiated in 1999, and is administered to institutionalized elderly subjects and to those recently hospitalized because of pneumonia (5,6).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Simonsen

Brandão

Brandileone

et al. 2005

Braz J Med Biol Res

View full text Add to dashboard Cite

Serum antibodies specific for the capsular polysaccharides of Streptococcus pneumoniae provide protection against invasive pneumococcal infection. In Brazil, this vaccine has been used for people over 65 years with clinical risk to develop pneumococcal infection since 1999. We evaluated the immune response of 102 elderly subjects (75.5% females and 24.5% males) with a mean age of 71 years, and 19 young healthy adults (63.2% females and 36.8% males) with a mean age of 27 years. The elderly study group consisted of outpatients who received follow-up care in the Geriatric Department of General Hospital, Faculty of Medicine, University of São Paulo. None had acute illness at the time of vaccination. Both groups were immunized with one intra-deltoid injection with 0.5 ml of a 23-valent pneumococcal polysaccharide vaccine. The total IgG specific antibody concentrations to capsular polysaccharides 1, 3, 5, 6B, 8, and 14 were determined against pre-and 1-month post-vaccination sera. All samples were analyzed according to the second-generation pneumococcal polysaccharide ELISA protocol. We observed that the pneumococcal polysaccharide vaccine evoked consistent antibody increase for serotypes 1, 5, 6B, 8, and 14 (geometric mean concentration increase of 2.46 in the elderly and 2.84 in the young adults). Otherwise, we observed no increase in antibody concentration for serotype 3 in both groups.

show abstract

Safety of Simultaneous Pneumococcal and Influenza Vaccination in Elderly Patients in Brazil

Cited by 10 publications

References 0 publications

Pneumococcal Vaccination and Revaccination of Older Adults

Pneumococcal Vaccination and Revaccination of Older Adults

Outbreak of influenza type A (H1N1) in Iporanga, São Paulo State, Brazil

Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly

Contact Info

Product

Resources

About